Leukocyte-associated immunoglobulin-like receptor-1 expressed in epithelial ovarian cancer cells and involved in cell proliferation and invasion

Cao, Qizhi; Fu, Aili; Yang, Shiming; He, Xiaoli; Wang, Yue; Zhang, Xiaoshu; Zhou, Jiadi; Luan, Xiying; Yu, Wenzheng; Xue, Jing

doi:10.1016/j.bbrc.2015.01.127

Cited by 23 publications

(28 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In ovarian cancer cells, the localization of LAIR1 was dependent on cell lines. LAIR-1 proteins were localized on both the plasma membrane and in the cytoplasm of COC1 cells, while predominately localized in the cytoplasm of HO8910 cells (26). Moreover, LAIR1 knockdown affected the cell proliferation in HO8910 cells, where LAIR1 was localized in the cytoplasm (26).…”

Section: Discussionmentioning

confidence: 95%

Leukocyte‑associated immunoglobulin‑like receptor�1 promotes tumorigenesis in RCC

et al. 2018

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, responsible for approximately 90-95% of cases. We previously reported a novel method that enables direct extraction of extracellular vesicles (EVs) from surgically resected viable tissues, yielding what we term tissue-exudative extracellular vesicles (Te-EVs). Quantitative LC/MS analysis identified 3,871 proteins in Te-EVs, among which leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) was highly enriched in tumor Te-EVs. In the present study, we found that LAIR1 was significantly upregulated in clinical specimens of human RCC tumor tissues compared to that noted in adjacent non-cancerous renal tissues as determined by quantitative PCR analysis. LAIR1 overexpression resulted in accelerated cell proliferation and tumor growth in RCC cells. Moreover, knockdown of LAIR1 using siRNA significantly inhibited cell proliferation in RCC cells. Mechanistically, LAIR1 upregulated the phosphorylation status of Akt, which in turn increased cell proliferation in RCC cells. In clinical RCC specimens, RCC patients with high LAIR1 mRNA expression showed poor progression-free survival compared to those with low LAIR1 expression. These findings indicate that LAIR1 promotes tumorigenesis in RCC.

show abstract

Section: Discussionmentioning

confidence: 95%

Leukocyte‑associated immunoglobulin‑like receptor�1 promotes tumorigenesis in RCC

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Researches have showed LAIR-1 overexpression as a consequential factor in the development of kidney and ovarian cancers. 19,33 Using bioinformatics analysis, we identified LAIR-1 overexpression in a broad range of tumor types, and in several tumors this expression significantly correlated with poor overall survival rates in patients. Taking advantage of the natural LAIR-2 regulatory system in humans, we established a recombinant LAIR-2-Fc fusion protein that can block the interaction between LAIR-1 and its ligand collagens.…”

Section: Discussionmentioning

confidence: 99%

Cancer immunotherapy based on blocking immune suppression mediated by an immune modulator LAIR-1

Wang

et al. 2020

OncoImmunology

View full text Add to dashboard Cite

The leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) is an inhibitory receptor expressed on the majority of peripheral blood mononuclear cells and is important for the regulation of immune responses. The binding of LAIR-1 to its ligands results in the loss of immune function in the tumor microenvironment (TME) and a reduction in T cell function and immune responses of antigen-presenting cells. Using bioinformatics analysis, we showed that LAIR-1 is broadly upregulated in multiple types of cancer. By designing a LAIR-2-Fc recombinant protein to block the binding of LAIR-1 to its ligand collagen, we observed augmented cytotoxic T cell infiltration and function resulting in antitumor immune responses that eliminated cancer cells. Besides, LAIR-2-Fc fusion protein potentiated the antitumor effect of PD-1/L1 checkpoint blockade therapy. Collectively, our results support the targeting of LAIR-1 for potential immunotherapeutic applications.

show abstract

“…Poggi et al (10) demonstrated that LAIR-1 was not expressed in high-risk B-cell chronic lymphocytic leukemia (CLL), and the intensity of expression in low- and intermediate-risk CLL was associated with the CLL stage and progression of the disease. However, a limited amount of attention has focused on LAIR-1 expression in solid tumors (11). The extracellular matrix (ECM) has been determined to promote the progression of a solid tumor (12).…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of leukocyte-associated immunoglobulin-like receptor-1 expression in human cervical cancer

Wang

Zhang

Miao

et al. 2016

Experimental and Therapeutic Medicine

Self Cite

View full text Add to dashboard Cite

Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is broadly expressed on the majority of immune cells; however, the biological role of LAIR in solid tumors has yet to be elucidated. In the present study, using immunohistochemical staining analysis, the expression of LAIR-1 in human cervical cancer (HCC) and nontumor-adjacent tissue specimens was determined, and the results indicated that the expression of LAIR-1 in HCC tissue was higher compared with that in noncancerous tissue. The χ2 test was used to analyze the correlation between the expression of LAIR-1 in tumor tissues with clinicopathological parameters. The results showed that the expression of LAIR-1 in the cancer cell nucleus was significantly associated with tumor size, pathological differentiation, T classification and clinical stage. In addition, the expression in the cytoplasm was evidently associated with the number of positive lymph nodes. The HCC cell line, ME-180, which does not express LAIR-1, was stably transfected using LAIR-1 cDNA. Cell Counting Kit-8 and an annexin V assay showed that the overexpression of LAIR-1 in ME-180 cells suppressed the proliferation and anti-apoptosis capacity of the cells. These findings demonstrated that LAIR-1 is markedly overexpressed in HCC tissue, and that its expression status is associated with tumor progression. LAIR-1 may be a biomarker and target in the diagnosis and treatment of patients with HCC.

show abstract

Leukocyte-associated immunoglobulin-like receptor-1 expressed in epithelial ovarian cancer cells and involved in cell proliferation and invasion

Cited by 23 publications

References 17 publications

Leukocyte‑associated immunoglobulin‑like receptor�1 promotes tumorigenesis in RCC

Leukocyte‑associated immunoglobulin‑like receptor�1 promotes tumorigenesis in RCC

Cancer immunotherapy based on blocking immune suppression mediated by an immune modulator LAIR-1

Clinical significance of leukocyte-associated immunoglobulin-like receptor-1 expression in human cervical cancer

Contact Info

Product

Resources

About